FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

FDA Updates Bioequivalence Guidance for Generic Topical Corticosteroids

[ Price : $8.95]

FDA finalizes updated guidance for industry outlining current recommendations for demonstrating bioequivalence of generic topical ...

Hearing to Examine FDA's Role in Strengthening U.S. Drug Development

[ Price : $8.95]

The House Energy and Commerce Subcommittee on Health plans a hearing 7/15 to examine how FDA can help strengthen U.S. leadership i...

FDA Finalizes Guidance on Formal Meetings for OTC Monograph Drugs

[ Price : $8.95]

The agency posts a final guidance that provides recommendations for formal meetings between the agency and sponsors or requestors ...

Proposed Rule to Modernize Drug Manufacturing Registration

[ Price : $8.95]

FDA proposed a rule seeks to modernize drug establishment registration requirements by creating a streamlined pathway for distribu...

Agency Sends 3rd Complete Response on Hengrui, Elevar NDA

[ Price : $8.95]

FDA sends Hengrui Pharma and Elevar Therapeutics a third complete response letter for their combination of camrelizumab and rivoce...

FDA Restarts Complete Response Letter Postings

[ Price : $8.95]

FDA resumes posting complete response letters just days after HHS confirmed that new rejection letter releases had been halted tem...

Subcutaneous Sarclisa with On-Body Injector Approved

[ Price : $8.95]

FDA approves a new subcutaneous formulation of Sanofi's anti-CD38 monoclonal antibody Sarclisa (isatuximab-irfc), allowing the the...

FDA Inspection Cites SGS North America Contract Laboratory

[ Price : $8.95]

An FDA inspection of SGS North America's contract testing laboratory identifies significant concerns with the firms laboratory con...

FDA Expands Approval of Keytruda-Enfortumab Vedotin Regimen

[ Price : $8.95]

FDA has expanded the indication for Merck's Keytruda (pembrolizumab), including its subcutaneous formulation Keytruda Qlex (pembro...

FDA Fast Tracks Arialys ART5803

[ Price : $8.95]

FDA grants Fast Track designation to Arialys Therapeutics ART5803 to treat anti-NMDA receptor encephalitis.